MedTrace Logo

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness

NCT05705063 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-01-30

No results posted yet for this study

Summary

To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or are currently taking psychotropic medications experiencing metabolic side effects.

Conditions

  • Bipolar Disorder I
  • Bipolar II Disorder
  • Bipolar I Disorder
  • Bipolar Disorder
  • Bipolar Depression
  • Bipolar and Related Disorders
  • Bipolar Disorder, Type 1
  • Bipolar Disorder, Type 2
  • Bipolar Disorder, Mixed
  • Obesity
  • Metabolic Syndrome
  • Ketogenic Dieting
  • Weight Gain
  • Brain Metabolic Disorder
  • Psychotropic Agents Causing Adverse Effects in Therapeutic Use

Interventions

OTHER

LCHF Ketogenic Diet

Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 6 weeks

Sponsors & Collaborators

Principal Investigators

  • Shebani Sethi, MD · Stanford University Dept Psychiatry and Behavioral Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2024-06-30
Completion
2024-12-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05705063 on ClinicalTrials.gov